Sichenzia Ross Ference LLP Represents Aegis Capital in $12.1 Million Follow-On Offering of BiondVax Pharmaceuticals Ltd. American Depositary Shares

Press Release – New York, NY – February 2, 2021 – Sichenzia Ross Ference LLP announced today that it represented Aegis Capital Corp. as sole book runner in the follow-on offering of 2,434,783 American Depositary Shares (“ADSs”) of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, at an offering price of $4.95 per ADS for gross proceeds of $12.1 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public at the public offering price

The ADSs are being offered by the Company pursuant to a “shelf” registration statement on Form F-3 (333-240189) filed with the SEC and declared effective by the SEC on August 10, 2020.

The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin M. Ocasio and Barrett S. DiPaolo and associate Jacob Tabman.

Author
Recent Posts

Sichenzia Ross Ference Carmel LLP

Sichenzia Ross Ference Carmel LLP is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation department specializes in defending companies and individuals against all types of securities cases, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations. The litigation team has also brought defamation lawsuits against companies and individuals related to market manipulation. Additionally, it represents individuals and companies in investigations by the Securities and Exchange Commission (SEC) and other regulatory bodies. The litigation team has a robust practice representing brokers and broker-dealers in arbitrations before the Financial Industry Regulatory Authority (FINRA). These arbitrations typically involve claims of unsuitability, churning, unauthorized trading and other allegations of broker misconduct. Finally, SRF has a burgeoning expungement practice, where it represents brokers seeking to have negative and harmful customer complaints removed from their industry records. The firm complements its core practice areas with an established commercial real estate and trusts and estates practice.

Visit SRFC's LinkedIn page

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

Sichenzia Ross Ference Carmel LLP Represents Aegis Capital Corp. in the $8.2 Million Private Placement of SOBRsafe, Inc. - October 8, 2024
Sichenzia Ross Ference Carmel LLP represents A2Z Cust2Mate Solutions Corp. in $4 Million Registered Direct Offering - October 2, 2024
Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.0 Million Offering - October 2, 2024

Sichenzia Ross Ference LLP Represents Aegis Capital in $12.1 Million Follow-On Offering of BiondVax Pharmaceuticals Ltd. American Depositary Shares

Related Posts